Financial Performance
5Y price score: (13)
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 279.7%
%
ㅤ
By default your notes are visible only to you.
180.2
52-week range
284.0
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
8.7 %
Dividend Yield TTM
1.1 %
Market cap $
$ 32,889
Price / Earnings TTM
21.8
Price / Book TTM
5
PEG TTM
2.3
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
(18.9) %
(7.1) %
279.7 %
Free cash flow per share growth
229.2 %
168.8 %
235.7 %
Earnings per share growth
2.3 %
221 %
317.7 %
Founded: 1,989
Employees: 9,980
Business Summary:
Q&A
Contribute
By providing well-researched and detailed answer you increase your chance of becoming Top Contributor. TopFunds is free for all top contributors. Learn more
Latest Earnings Call Takeaways
2026 Q4 (Aug 6, 2026)
1) Strong Financial Performance
- ResMed reported Q4 revenue of $1.5 billion, reflecting a 9% increase YoY, or 8% on a constant-currency basis.
- Non-GAAP earnings per share (EPS) grew by 16% to $2.95.
- For FY 2026, total revenue grew 10% YoY, with non-GAAP EPS increasing by 17%.
- Free cash flow for the quarter was $404 million, down 21% YoY, primarily due to a $42 million provision related to the Astral device recall.
2) Strategic Focus and Operational Excellence
- ResMed's strategy for FY 2027 emphasizes operational excellence, innovation, and active portfolio management.
- The company is focusing on expanding its digital health ecosystem, particularly in sleep health and breathing health.
- Partnerships, such as with Oura, aim to enhance sleep health awareness and intervention.
- The company is also integrating the Noctrix acquisition to expand its product offerings in sleep disorders.
3) Challenges and Headwinds
- A significant headwind for FY 2027 is the $75 million revenue impact from suspending sales of the Astral devices due to a field safety notice.
- Life support device revenue saw a 45% decline in The Americas, contributing to overall challenges in that segment.
- Inflationary pressures are impacting gross margins, with a 90 basis point increase YoY but a 50 basis point decline sequentially from Q3 to Q4.
4) Product Innovations and Market Expansion
- The AirSense 11 continues to be a key product, with ongoing global rollout and enhancements in patient engagement through digital platforms.
- New product launches, including the AirCurve 11 and novel fabric technology masks, are expected to drive future growth.
- ResMed is committed to continuous innovation, with increased R&D spending by 22% YoY to support next-gen devices and AI-driven solutions.
5) Guidance and Outlook
- For FY 2027, ResMed expects revenue growth in the range of 5% to 7%, with non-GAAP EPS guidance of $12 to $12.25.
- The company plans to return over $1.85 billion to shareholders through dividends and share repurchases, marking a 75% increase YoY.
- The guidance reflects ongoing challenges from the Astral device situation but anticipates strong underlying growth in core sleep devices and masks.
Bottom line: ResMed is positioned for continued growth despite headwinds from the Astral device recall and inflationary pressures. With a strong focus on innovation and operational excellence, the company aims to leverage its market leadership in sleep health to drive shareholder value in FY 2027 and beyond.
Annual Reports, Presentations And IR Contacts
Go to the websiteResMed — Financial Overview, Stock Price, Market Cap
ResMed is a company. Founded in 1989. As of October 9, 2026, the company's market capitalization is $32888633944 with a current stock price of $226.73.